- Home
- BMRN
as 03-25-2025 12:31pm EST
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 13.7B | IPO Year: | 1999 |
| Target Price: | $94.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.21 | EPS Growth: | 153.71 |
| 52 Week Low/High: | $60.63 - $94.85 | Next Earning Date: | 04-23-2025 |
| Revenue: | $2,853,915,000 | Revenue Growth: | 17.97% |
| Revenue Growth (this year): | 12.23% | Revenue Growth (next year): | 9.90% |
Stock Insider Trading Activity of BioMarin Pharmaceutical Inc. (BMRN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burkhart Erin | BMRN | GVP, Chief Accounting Officer | Feb 24 '25 | Sell | $68.38 | 1,344 | $91,902.72 | 13,105 |
Latest BioMarin Pharmaceutical Inc. News
BMRN Breaking Stock News: Dive into BMRN Ticker-Specific Updates for Smart Investing
StockStory
2 days ago
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Zacks
5 days ago
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue?
Zacks
5 days ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
StockStory
5 days ago
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Monkey
6 days ago
BioMarin Pharmaceutical (BMRN): Among Paul Singer’s Latest Portfolio’s Top Stock Picks
PR Newswire
6 days ago
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
StockStory
6 days ago
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
StockStory
7 days ago
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Compare BMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMRN BioMarin Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.